Prenetics Raises Full-Year IM8 Guidance to $210M After Q1 Revenue Soars 334%
Prenetics posted Q1 2026 revenue of $36 million, up 334% year-on-year, led by IM8’s $33.8 million in sales and lifted full-year IM8 guidance to $190–210 million. It also appointed Brian J. Rosin as IM8’s U.S. CFO and executed $19 million of share buybacks to fund global expansion.
1. Q1 2026 Financial Highlights
Prenetics recorded Q1 revenue of $36.0 million, a 334% increase year-on-year, with IM8 contributing $33.8 million, up 23% from Q4. Gross profit reached $23.3 million, and the company raised full-year IM8 revenue guidance to $190–210 million while projecting Q2 revenue of $46–48 million.
2. Operational Initiatives
In Q1, Prenetics launched three new IM8 SKUs—Hydration, Creatine and Kids’ Gummies—divested its digital assets for $41.3 million, and executed $19 million of its $40 million share buyback program to strengthen the balance sheet.
3. Executive Appointment
Brian J. Rosin joined IM8 as U.S. Chief Financial Officer, bringing nearly two decades of finance leadership in premium wellness and e-commerce. He will oversee financial strategy, capital allocation and investor relations to support IM8’s rapid global expansion.
4. IM8 Global Expansion
IM8 has surpassed $100 million in annualized recurring revenue within 11 months of launch, is sold in more than 40 countries and is projecting $190–210 million in 2026 revenue. The brand’s premium positioning and science-backed formulations have driven strong unit economics and subscription retention.